Obesity
is a major growing health concern around the world. In most markets, a person
is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per
square meter (kg/m2), calculated by dividing body mass in kilograms by height
in meters squared. With the global prevalence continuing to rise, the disease
has placed significant burden on healthcare expenditure, as it is also a major
risk factor for cardiovascular diseases, diabetes and cancer.
Browse Full Report
Visit - http://www.acutemarketreports.com/report/frontier-pharma-obesity-identifying-and-commercializing-first-in-class-innovation
Anti-obesity
pharmacotherapy can be used as an adjunct lifestyle modification to improve
weight loss in order to significantly reduce obesity-associated health risks in
obese patients. However, the use of currently available anti-obesity drugs is
largely limited by poor long-term safety and a modest weight loss effect.
Despite substantial clinical and regulatory challenges, the early-stage obesity
pipeline remains robust, containing a high level of first-in-class innovation
that has the potential to be translated into effective and safe weight loss
treatments.
1 Table of Contents
1
Table of Contents 2
1.1
List of Tables 3
1.2
List of Figures 3
Browse All Reports
of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
2 Executive Summary
4
2.1
High Unmet Need Remains in the Obesity Market 4
2.2
Highly Innovative and Diverse Pipeline 4
2.3
Deals Landscape Presents Substantial Investment Opportunities 4
3 The Case for
Innovation 5
3.1
Growing Opportunities for Biologic Products 6
3.2
Diversification of Molecular Targets 6
3.3
Innovative First-in-Class Product Developments Remain Attractive 6
3.4
Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product
Innovation 7
3.5
Sustained Innovation 7
3.6
GBI Research Report Guidance 8
Send An Enquiry - http://www.acutemarketreports.com/request-free-sample/48776
4 Clinical and
Commercial Landscape 9
4.1
Disease Overview 9
4.2
Disease Etiology 9
4.2.1
Genetics 9
4.3
Disease Pathophysiology 10
4.3.1
Central Regulation of Energy Homeostasis 10
4.3.2
Endocrine Regulation in Energy Balance 11
4.3.3
Adipose Tissue and Regulation of Energy Expenditure 11
4.3.4
Dysregulation of Adipokines and Contribution to Obesity and Related Metabolic
Disorders 12
4.4
Epidemiology 13
4.5
Classification and Diagnosis 13
4.6
Co-morbidities 14
4.6.1
Type 2 Diabetes 14
4.6.2
Hypertension 14
4.6.3
Dyslipidemia and Cardiovascular Diseases 14
4.6.4
Respiratory Complications 14
About - Acute Market Reports :
Acute
Market Reports is the most sufficient collection of market intelligence
services online. It is your only source that can fulfill all your market
research requirements.We provide online reports from over 100 best publishers
and upgrade our collection regularly to offer you direct online access to the
world’s most comprehensive and recent database with expert perceptions on
worldwide industries, products, establishments and trends.
Our
team consists of highly motivated market research professionals and they are
accountable for creating the groundbreaking technology that we utilize in our
search engine operations to easily recognize the most current market research
reports online.
Contact Us :
Chris Paul
ACUTE MARKET
REPORTS
Office
No 101, 1st Floor ,
Aditi
Mall, Baner,
Pune,
MH, 411045
India
Toll
Free(US/CANADA): +1-855-455-8662
India:
+91 7755981103
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com/